GlassScriptPhysician profile
Barrett J Wallis
NPI 1740220938
$3,433.82
in general payments reported to CMS, 2019-2025
24 companies · $1,198 in 2025
The $1,198 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $170 · 2021: $566 · 2022: $244 · 2023: $506 · 2024: $489 · 2025: $1,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,193.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $643.57 | 2021-2025 | |
| Abbvie INC. | $625.56 | 2019-2025 | Viberzi, Linzess |
| Janssen Biotech, INC. | $466.10 | 2019-2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $225.76 | 2019-2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $208.82 | 2019-2023 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $179.76 | 2020-2025 | Entyvio, Gattex |
| Medtronic, INC. | $157.34 | 2021-2025 | Endoflip, Pillcam |
| Boston Scientific Corporation | $136.43 | 2025 | Exalt Model D |
| Celgene Corporation | $134.64 | 2021-2024 | Zeposia |
| Lucid Diagnostics INC. | $122.65 | 2023-2024 | |
| Fujifilm Healthcare Americas Corporation | $117.99 | 2023-2025 | Fujifilm |
| E.R. Squibb & Sons, L.L.C. | $109.98 | 2022 | |
| Madrigal Pharmaceuticals | $59.90 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $59.18 | 2024 | |
| Amgen INC. | $25.51 | 2025 | Uplizna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $24.09 | 2024 | Ibsrela |
| Concordia Pharmaceuticals INC. | $23.06 | 2019 | |
| Alnylam Pharmaceuticals INC. | $22.90 | 2021 | |
| Braintree Laboratories, INC. | $19.42 | 2021 | |
| Novo Nordisk INC | $17.39 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $16.06 | 2021 | |
| Ferring Pharmaceuticals INC. | $15.10 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.69 | 2020 | |
| Merit Medical Systems INC | $10.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barrett Wallis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.